YMAB vs. SIGA, ARCT, COGT, PRTC, AUPH, SAGE, IRON, SVRA, LBPH, and WVE
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include SIGA Technologies (SIGA), Arcturus Therapeutics (ARCT), Cogent Biosciences (COGT), PureTech Health (PRTC), Aurinia Pharmaceuticals (AUPH), Sage Therapeutics (SAGE), Disc Medicine (IRON), Savara (SVRA), Longboard Pharmaceuticals (LBPH), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical preparations" industry.
SIGA Technologies (NASDAQ:SIGA) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.
Y-mAbs Therapeutics has a consensus target price of $16.57, suggesting a potential upside of 34.95%. Given SIGA Technologies' higher probable upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than SIGA Technologies.
SIGA Technologies has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Y-mAbs Therapeutics received 113 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 60.51% of users gave Y-mAbs Therapeutics an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote.
In the previous week, Y-mAbs Therapeutics had 6 more articles in the media than SIGA Technologies. MarketBeat recorded 16 mentions for Y-mAbs Therapeutics and 10 mentions for SIGA Technologies. Y-mAbs Therapeutics' average media sentiment score of 0.47 beat SIGA Technologies' score of 0.11 indicating that SIGA Technologies is being referred to more favorably in the media.
55.4% of SIGA Technologies shares are held by institutional investors. Comparatively, 70.8% of Y-mAbs Therapeutics shares are held by institutional investors. 2.2% of SIGA Technologies shares are held by insiders. Comparatively, 21.5% of Y-mAbs Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
SIGA Technologies has a net margin of 48.65% compared to SIGA Technologies' net margin of -25.26%. Y-mAbs Therapeutics' return on equity of 44.84% beat SIGA Technologies' return on equity.
SIGA Technologies has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
SIGA Technologies beats Y-mAbs Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
